RxDoctor Payments Data

Grace Obrien, DO

Family Medicine · South Ogden, UTNPI 1093702003

Payments from drug & device makers

$7,537in general payments, 2019–2025

Across 466 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$797
  • AstraZeneca$450
  • Amarin Pharma, Inc.$411
  • Astellas Pharma US Inc$408
  • Abbott$377
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$7,34797%
  • Education$1903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)108$1,476
Amgen36$797
AstraZeneca23$450
Amarin Pharma, Inc.34$411
Astellas Pharma US Inc17$408
Abbott13$377
Lilly USA, LLC24$370
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC27$293
Novo Nordisk15$257
Pfizer13$243
GSK12$184
Biohaven Pharmaceuticals, Inc.11$147
Teva Pharmaceuticals USA, Inc.10$133
Sanofi-aventis U.S. LLC10$132
Johnson & Johnson8$117
Baxter Healthcare2$90
Takeda Pharmaceuticals U.S.A., Inc.6$90
Dynavax Technologies Corporation5$75
Axsome Therapeutics, Inc.3$67
Biogen4$65
Biohaven Pharmaceutical Holding Company Ltd.3$65
Currax Pharmaceuticals LLC4$58
Sumitomo Pharma America, Inc.4$57
Antares Pharma, Inc.4$52
Kowa Pharmaceuticals America, Inc.4$52
Lundbeck LLC3$51
Organon3$50
Arbor Pharmaceuticals, Inc.3$50
Neurocrine Biosciences, Inc.3$48
Upsher-smith Laboratories LLC2$46
Almatica Pharma LLC2$46
Boehringer Ingelheim3$44
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$41
Endo Pharmaceuticals Inc.3$40
Ardelyx, Inc.2$40
Novartis3$36
Hologic Sales And Service, LLC1$36
Vifor Pharma, Inc.2$35
E.r. Squibb & Sons, L.L.C.2$35
Supernus Pharmaceuticals, Inc.2$34
Sunovion Pharmaceuticals Inc.4$32
Edwards Lifesciences1$26
Bausch Health US, LLC2$25
Daiichi Sankyo Inc.1$24
Dexcom, Inc.1$24
Otsuka America Pharmaceutical, Inc.1$22
Cranial Technologies, Inc1$17
Exact Sciences1$16
Genentech USA, Inc.1$16
Tris Pharma Inc1$16
Idorsia Pharmaceuticals US Inc1$16
Therapeuticsmd, Inc.1$15
Eisai Inc.1$15
Lucid Diagnostics Inc.1$15
Acella Pharmaceuticals, LLC1$15
Sanofi Pasteur Inc.1$15
Shire North American Group Inc1$15
Kaleo, Inc.1$14
Medtronic1$14
Phathom Pharmaceuticals, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,537 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$176,651
Medicare patients
382
Services billed
6,792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$101,473
EliquisApixaban56$50,184
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$28,478
MyrbetriqMirabegron23$24,696
FarxigaDapagliflozin Propanediol31$22,778
XareltoRivaroxaban27$18,946
Lantus SolostarInsulin Glargine,hum.Rec.Anlog78$16,100
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog27$13,722
TrulicityDulaglutide14$13,303
LinzessLinaclotide20$12,501
GemtesaVibegron12$9,484
Levothyroxine Sodium829$8,783
Omeprazole369$7,720
Potassium Chloride174$6,013
Lyumjev Kwikpen U-100Insulin Lispro-Aabc11$5,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$257$101,47393 claims
PfizerEliquis, Premarin$243$54,46967 claims
GSKTrelegy Ellipta, Breo Ellipta$184$33,97340 claims
AstraZenecaFarxiga, Symbicort$450$28,16450 claims
Astellas Pharma US IncMyrbetriq$408$24,69623 claims
Johnson & JohnsonXarelto$117$18,94627 claims
AbbVieLinzess, Synthroid$1,476$15,08361 claims
Lilly USA, LLCTrulicity$370$13,30314 claims
Sumitomo Pharma America, Inc.Gemtesa$57$9,48412 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$90$4,68612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 928 family medicine providers in Utah.

Other family medicine in South Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →